Iradimed Corp
IRMD
Surgical & Medical Instruments & Apparatus
Mkt Cap
$546.3MPE
30.48Debt
-Cash
$45.13MEV
-FCF
$11.39MP/E Ratio
30.48Debt
-Cash
$45.13MEV
-FCF
$11.39MCharts data: {"Earnings":[{"time":"2014-12-30","value":2050366},{"time":"2015-12-30","value":7529920},{"time":"2016-12-30","value":7214545},{"time":"2017-12-30","value":499764},{"time":"2018-12-30","value":6303450},{"time":"2019-12-30","value":9630959},{"time":"2020-12-30","value":1369001},{"time":"2021-12-30","value":9325471},{"time":"2022-12-30","value":12828487},{"time":"2023-12-30","value":17192776}],"Sales":[{"time":"2014-12-30","value":15653057},{"time":"2015-12-30","value":31593720},{"time":"2016-12-30","value":32496548},{"time":"2017-12-30","value":23081592},{"time":"2018-12-30","value":30438983},{"time":"2019-12-30","value":38517141},{"time":"2020-12-30","value":31717372},{"time":"2021-12-30","value":41814581},{"time":"2022-12-30","value":53303145},{"time":"2023-12-30","value":65562296}],"Net Margins":[{"time":"2014-12-30","value":0.13098821527322108},{"time":"2015-12-30","value":0.2383359730984512},{"time":"2016-12-30","value":0.22200958083301647},{"time":"2017-12-30","value":0.021652059355351225},{"time":"2018-12-30","value":0.2070847767811428},{"time":"2019-12-30","value":0.250043454679048},{"time":"2020-12-30","value":0.04316249782611245},{"time":"2021-12-30","value":0.22301959692003132},{"time":"2022-12-30","value":0.24067035819368632},{"time":"2023-12-30","value":0.2622357215799764}],"Assets":[{"time":"2014-12-30","value":23309719},{"time":"2015-12-30","value":35244207},{"time":"2016-12-30","value":37194484},{"time":"2017-12-30","value":39012534},{"time":"2018-12-30","value":48442258},{"time":"2019-12-30","value":66728864},{"time":"2020-12-30","value":71066620},{"time":"2021-12-30","value":82881422},{"time":"2022-12-30","value":85513747},{"time":"2023-12-30","value":92156098}],"Stockholders Equity":[{"time":"2014-12-30","value":20890696},{"time":"2015-12-30","value":31933025},{"time":"2016-12-30","value":31889125},{"time":"2017-12-30","value":32930877},{"time":"2018-12-30","value":41945733},{"time":"2019-12-30","value":55524395},{"time":"2020-12-30","value":61384612},{"time":"2021-12-30","value":72173806},{"time":"2022-12-30","value":73672987},{"time":"2023-12-30","value":71420164}],"ROE":[{"time":"2014-12-30","value":0.09814732836091243},{"time":"2015-12-30","value":0.23580352941821203},{"time":"2016-12-30","value":0.22623841199782058},{"time":"2017-12-30","value":0.015176152156530785},{"time":"2018-12-30","value":0.15027631058444013},{"time":"2019-12-30","value":0.17345455092306725},{"time":"2020-12-30","value":0.022302022532943597},{"time":"2021-12-30","value":0.12920852476589637},{"time":"2022-12-30","value":0.17412741796392753},{"time":"2023-12-30","value":0.24072719855417862}],"ROA":[{"time":"2014-12-30","value":0.13152839809008424},{"time":"2015-12-30","value":0.33011195286646683},{"time":"2016-12-30","value":0.2944719975144702},{"time":"2017-12-30","value":0.03579326582579845},{"time":"2018-12-30","value":0.12793183587767523},{"time":"2019-12-30","value":0.1355233171660168},{"time":"2020-12-30","value":-0.00868027774502291},{"time":"2021-12-30","value":0.11867903279941312},{"time":"2022-12-30","value":0.1892181031431122},{"time":"2023-12-30","value":0.23588516084958372}]}
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Sector
![GKOS Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>GKOS</text></svg>){kind=small}
![GMED Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>GMED</text></svg>){kind=small}
DCF
Discounted Cash Flow Valuation of Iradimed Corp
Value
Growth
%
%
Discount
%
%
Multiple
| g\r | +10% | +11% | +12% | +13% | +14% |
|---|---|---|---|---|---|
| 0% | 10 | 9 | 8 | 8 | 7 |
| +1% | 11 | 10 | 9 | 8 | 8 |
| +2% | 13 | 11 | 10 | 9 | 8 |
| +3% | 14 | 13 | 11 | 10 | 9 |
| +4% | 17 | 14 | 12 | 11 | 10 |
| Years | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | TV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FCF | $11.39M | $12.12M | $12.88M | $13.67M | $14.48M | $15.32M | $16.18M | $17.07M | $17.98M | $18.9M | $19.85M | $198.5M |
| DCF | $10.54M | $9.739M | $8.986M | $8.279M | $7.617M | $6.996M | $6.417M | $5.877M | $5.374M | $4.907M | $49.07M | |
| Value | $123.8M | |||||||||||
In the chart Earnings are multiplied by this value.
Earnings Growth 15%
Earnings Stability 19%
Competitiveness and MOAT
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
| Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 24% | 22% | 2.2% | 21% | 25% | 4.3% | 22% | 24% | 26% | 26% |
| ROA | 33% | 29% | 3.6% | 13% | 14% | -0.87% | 12% | 19% | 24% | 26% |
| ROE | 24% | 23% | 1.5% | 15% | 17% | 2.2% | 13% | 17% | 24% | 24% |
What is the average Net Margin?
The average Net Margin over the past 5 years is +20.44%.
What is the trend of Net Margin?
The trend of Net Margin over the past 5 years is +1.22%.
What is the average Return on Assets (ROA)?
The average ROA over the past 5 years is +13.31%.
What is the trend of Return on Assets (ROA)?
The trend of ROA over the past 5 years is +2.37%.
What is the average Return on Equity (ROE)?
The average ROE over the past 5 years is +14.83%.
What is the trend of Return on Equity (ROE)?
The trend of ROE over the past 5 years is +1.6%.
Safety & Stabiliy
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
| Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt FCF | - | - | - | - | - | - | - | - | - | - |
| Debt Equity | - | - | - | - | - | - | - | - | - | - |
| MIN | ||||||||||
| Graham Stability | - | - | 8.9% | 100% | 100% | 25% | 100% | 100% | 100% | 8.9% |
What is the Debt/FCF?
The Debt/FCF trailing twelve month is -.
What is the trend of Debt/FCF?
The trend of Debt/FCF over the past 5 years is -.
What is the Graham’s Stability?
Graham’s Stability measure stands at 0.09.
Growth
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
| Years | 12-2016 | 12-2018 | 12-2020 | 12-2022 | Trend |
|---|---|---|---|---|---|
| Revenue | 11% | 17% | 27% | 23% | -2.8% |
| Net Income | 13% | 22% | 130% | 34% | -12% |
| Stockholders Equity | 12% | 11% | 5.2% | -3.1% | -3.4% |
| FCF | -5% | -3.4% | 3.9% | -33% | -20% |
What is the 5 year Revenue CAGR?
The Revenue CAGR over the past 5 years is +16.59%.
What is the trend of Revenue growth?
The trend of Revenue growth rate over the past 5 years is -2.82%.
What is the 5 year Earnings CAGR?
The Earnings CAGR over the past 5 years is +22.22%.
What is the trend of Earnings growth?
The trend of Earnings growth rate over the past 5 years is -11.77%.
What is the 5 year Equity CAGR?
The Equity CAGR over the past 5 years is +11.23%.
What is the trend of Equity growth?
The trend of Equity growth rate over the past 5 years is -3.42%.
What is the 5 year FCF CAGR?
The FCF CAGR over the past 5 years is -3.36%.
What is the trend of FCF growth?
The trend of FCF growth rate over the past 5 years is -19.65%.